Abstract
To determine the clinical and immunological effects of Iscador in children suffering from recurrent respiratory disease as a result of the Chernobyl nuclear accident, a non-randomized, placebo-controlled trial was carried out at a specialist paediatric setting in Kiev. Twice-weekly injections of saline for 3 weeks were followed by twice-weekly injections of Iscador for 3 weeks. The outcome measures were clinical symptoms, counts of main lymphocyte subsets, PHA-lymphocyte response, NK activity and phagocytosis. Improvements in clinical and many immunological parameters were seen after treatment with Iscador, but not with placebo. Iscador appears to improve clinical symptoms and markers of immune function in children suffering recurrent respiratory disease after Chernobyl.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
